natgillin/translations-raw huggingface dataset:
As for all medicines, data on the use of Kyprolis is continuously monitored. 
Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Kyprolis stalno spremljajo.
This means that it blocks the proteasome, which is a system within the cells that breaks down proteins that are no longer needed. 
To pomeni, da zavira proteasom, tj. sistem v celicah, ki razgrajuje beljakovine, ko te niso več potrebne.
The most serious side effects include toxic effects on the heart, lungs and liver, and hypertension (high blood pressure) that can be severe. 
Najresnejši neželeni učinki vključujejo toksične učinke na srce, pljuča in jetra ter hipertenzijo (visok krvni tlak), in so lahko zelo resni.
The Agency noted the unmet medical need for patients with multiple myeloma who no longer improve with the available therapies. 
Agencija je opozorila na neizpolnjene medicinske potrebe pri bolnikih z multiplim mielomom, ki se ne odzivajo več na razpoložljivo zdravljenje.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Kyprolis have been included in the summary of product characteristics and the package leaflet. 
Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Kyprolis upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
What benefits of Kyprolis have been shown in studies? 
Kakšne koristi zdravila Kyprolis so se pokazale v študijah?
Why is Kyprolis authorised in the EU? 
Zakaj je bilo zdravilo Kyprolis odobreno v EU?
An overview of Kyprolis and why it is authorised in the EU 
Pregled zdravila Kyprolis in zakaj je odobreno v EU
For more information about using Kyprolis, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij glede uporabe zdravila Kyprolis glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
Side effects reported with Kyprolis are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Kyprolis, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Kyprolis can only be obtained with a prescription and treatment must be supervised by a doctor experienced in the treatment of cancer. 
Predpisovanje in izdaja zdravila Kyprolis je le na recept, zdravljenje pa mora nadzorovati zdravnik z izkušnjami z zdravljenjem raka.
Multiple myeloma is rare, and Kyprolis was designated an ‘orphan medicine' (a medicine used in rare diseases) on 3 June 2008. 
Multipli mielom je redka bolezen, zato je bilo zdravilo Kyprolis 3. junija 2008 določeno kot „zdravilo sirota“ (zdravilo za zdravljenje redkih bolezni).
What are the risks associated with Kyprolis? 
Kakšna tveganja so povezana z zdravilom Kyprolis?
From cycle 13 onwards, the doses on day 8 and 9 are omitted if Kyprolis is used with lenalidomide and dexamethasone. 
Od trinajstega cikla naprej se odmerka 8. in 9. dan izpustita, če se Kyprolis uporablja skupaj z lenalidomidom in deksametazonom.
What is Kyprolis and what is it used for? 
Kaj je zdravilo Kyprolis in za kaj se uporablja?
It considered that the increase in time without the disease getting worse with Kyprolis was clinically meaningful. 
Ocenjeno je bilo, da je podaljšanje časa brez poslabšanja bolezni, ki so ga opazili pri zdravilu Kyprolis, klinično pomembno.
Other serious side effects are dyspnoea, acute kidney injury, tumour lysis syndrome (a complication due to the breakdown of cancer cells), infusion-related reactions, thrombocytopenia, internal bleeding, posterior reversible encephalopathy syndrome (a brain disorder that can cause headache, confusion, fits and loss of vision, and which may improve over time) as well as thrombotic microangiopathy and TTP/HUS (diseases involving problems with the blood clotting system). 
Drugi resni neželeni učinki so dispneja, akutna poškodba ledvic, sindrom tumorske lize (zaplet zaradi razgradnje rakavih celic), reakcije, povezane z infuzijo, trombocitopenija, notranje krvavitve, sindrom posteriorne reverzibilne encefalopatije (možganska motnja, ki se lahko kaže z glavobolom, zmedenostjo, krči in izgubo vida, ki pa se sčasoma izboljša), kot tudi trombotična mikroangiopatija in TTP/HUS (bolezni, za katere so značilne težave s sistemom strjevanja krvi).
When carfilzomib stops the proteasome from breaking down proteins in the cancer cells, the proteins build up and cause the cells to die, slowing down the growth of the cancer. 
Ko karfilozomib ustavi proteasom in tako prepreči razgrajevanje beljakovin v rakavih celicah, se te v celici kopičijo, celice pa sčasoma odmrejo, s čimer se upočasni rast raka.
Kyprolis must not be used in women who are breastfeeding. 
Zdravila Kyprolis ne smejo uporabljati doječe matere.
Regarding safety, although side effects, including severe effects, were seen with treatment involving Kyprolis, these were considered acceptable and manageable. 
Čeprav so bili pri zdravljenju z zdravilom Kyprolis opaženi neželeni učinki, vključno z resnimi neželenimi učinki, so bili ocenjeni kot sprejemljivi in obvladljivi.
Kyprolis is a cancer medicine used together with the medicines lenalidomide and dexamethasone or with dexamethasone alone, to treat multiple myeloma (a cancer of the bone marrow). 
Kyprolis je zdravilo za zdravljenje raka, ki se uporablja v kombinaciji z lenalidomidom in deksametazonom ali samo z deksametazonom za zdravljenje multiplega mieloma (raka kostnega mozga).
Treatment may need to be stopped or the dose reduced, if the disease gets worse or the patient has severe side effects. 
Če se bolezen poslabša ali če bolnik občuti resne neželene učinke, je zdravljenje treba po potrebi prekiniti ali odmerek zmanjšati.
The active substance in Kyprolis, carfilzomib, is a proteasome inhibitor. 
Zdravilna učinkovina zdravila Kyprolis, karfilzomib, je zaviralec proteasoma.
The most common side effects with Kyprolis (which may affect more than 1 in 5 people) are anaemia (low red blood cell counts), tiredness, nausea, diarrhoea, thrombocytopenia (low blood platelet counts), fever, dyspnoea (difficulty breathing), respiratory tract (airways) infection, cough and neutropenia (low levels of neutrophils, a type of white blood cell). 
Najpogostejši neželeni učinki zdravila Kyprolis (ki se lahko pojavijo pri več kot 1 bolniku od 5) so anemija (nizko število rdečih krvnih celic), utrujenost, navzeja (slabost), driska, trombocitopenija (nizko število trombocitov), povišana telesna temperatura, dispneja (težave z dihanjem), okužba respiratornega trakta (dihal), kašelj in nevtropenija (nenormalno znižanje števila nevtrofilcev, vrste belih krvničk).
Further information on Kyprolis can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Več informacij o zdravilu Kyprolis je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reportsPovzetek je bil nazadnje posodobljen 03-2018.
Kyprolis taken together with lenalidomide and dexamethasone has been compared with lenalidomide plus dexamethasone in one main study involving 792 patients with multiple myeloma whose disease had got worse after previous treatment. 
Zdravilo Kyprolis v kombinaciji z lenalidomidom in deksametazonom so primerjali z lenalidomidom in deksametazonom v eni glavni študiji pri 792 bolnikih z multiplim mielomom, pri katerih se je bolezen po predhodnem zdravljenju poslabšala.
Another study in 929 multiple myeloma patients whose disease had got worse after previous treatment compared the combination of Kyprolis and dexamethasone with bortezomib and dexamethasone. 
V drugi študiji so pri 929 bolnikih z multiplim mielomom, pri katerih se je bolezen poslabšala po predhodnem zdravljenju, primerjali kombinacijo zdravila Kyprolis in deksametazona z bortezomibom in deksametazonom.
Kyprolis is available as a powder to be made up into a solution for infusion (drip) into a vein. 
Zdravilo je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
After the first week the dose is increased if the side effects are manageable. 
Če so neželeni učinki obvladljivi, se odmerek po prvem tednu poveča.
The study showed that Kyprolis is effective at prolonging the time patients lived without their disease getting worse (progression-free survival): patients receiving Kyprolis with lenalidomide and dexamethasone lived on average for 26.3 months without their disease getting worse, compared with 17.6 months for patients receiving lenalidomide plus dexamethasone. 
Študija je pokazala, da je zdravilo Kyprolis učinkovito pri podaljševanju časa do ponovnega poslabšanja bolnikove bolezni (preživetje brez napredovanja): bolniki, ki so prejemali zdravilo Kyprolis skupaj z lenalidomidom in deksametazonom so povprečno živeli 26,3 meseca brez poslabšanja bolezni, bolniki, ki so prejemali samo lenalidomid in deksametazon, pa 17,6 meseca.
Cancer cells have an increased need to produce and break down proteins because they multiply rapidly. 
Rakave celice imajo zaradi svojega hitrega razmnoževanje povečano potrebo po proizvodnji in razgradnji beljakovin.
How does Kyprolis work? 
Kako zdravilo Kyprolis deluje?
The study showed that the combination of Kyprolis and dexamethasone is more effective at improving progression-free survival than bortezomib and dexamethasone: patients receiving Kyprolis plus dexamethasone lived for an average of 18.7 months without their disease getting worse, compared with 9.4 months for patients receiving bortezomib and dexamethasone. 
Študija je pokazala, da kombinacija zdravila Kyprolis z deksametazonom učinkoviteje izboljšuje preživetje brez napredovanja kot bortezomib in deksametazon: bolniki, ki so jemali zdravilo Kyprolis z deksametazonom, so v povprečju živeli 18,7 meseca brez poslabšanja bolezni v primerjavi z 9,4 meseca pri bolnikih, ki so prejemali bortezomib in deksametazon.
How is Kyprolis used? 
Kako se zdravilo Kyprolis uporablja?
Kyprolis contains the active substance carfilzomib. 
Zdravilo Kyprolis vsebuje zdravilno učinkovino karfilzomib.
Boulevard de la Plaine 17 1050 Brussels Belgium200 mg/100ml Solution for Infusion 
Boulevard de la Plaine 17 1050 Brussels Belgium200 mg/100ml raztopina za infundiranje
CT13 9NJ United Kingdom200 mg/100ml Solution for Infusion 
CT13 9NJ United Kingdom200 mg/100ml raztopina za infundiranje
Diflucan Derm Saft 
Diflucan Derm Saft sirup
Diflucan Saft 
Diflucan Saft sirup
Diflucan 2 mg/ml solución para perfusión 
Diflucan 2 mg/ml solución para perfusión raztopina za infundiranje
Diflucan mg/5 ml polvo para suspensión oral 
Diflucan mg/5 ml polvo para suspensión oral prašek za suspenzijo
Diflucan 40 mg/ml prašek za peroralno suspenzijo 
Diflucan 40 mg/ml prašek za peroralno suspenzijo prašek za suspenzijo
Diflucan 10 mg/ ml prašek za peroralno suspenzijo 
Diflucan 10 mg/ ml prašek za peroralno suspenzijo prašek za suspenzijo
Diflucan suspensie 200 200 mg/5ml 
Diflucan suspensie 200 200 mg/5ml prašek za suspenzijo
Diflucan i.v.-400mg 400 mg/200ml Solution for Infusion 
Diflucan i.v.-400mg 400 mg/200ml raztopina za infundiranje
Diflucan i.v.-200mg 200 mg/100ml Solution for Infusion 
Diflucan i.v.-200mg 200 mg/100ml raztopina za infundiranje
Diflucan 200 mg/5 ml polvo para suspensión oral 
Diflucan 200 mg/5 ml polvo para suspensión oral prašek za suspenzijo
Powder for Suspension 
Kent prašek za suspenzijo
400 mg/200ml Solution for Infusion 
400 mg/200ml raztopina za infundiranje
Diflucan 2 mg/ml šķīdums infūzijām 
Diflucan 2 mg/ml šķīdums infūzijām raztopina za infundiranje
Diflucan suspensie 50 50 mg/5ml 
Diflucan suspensie 50 50 mg/5ml prašek za suspenzijo
Capsule 
Kent kapsula
Diflucan i.v.-100mg 100 mg/50 ml 
Diflucan i.v.-100mg 100 mg/50 ml raztopina za infundiranje
Diflucan 40 mg/ml por belsőleges szuszpenzióhoz 
Diflucan 40 mg/ml por belsőleges szuszpenzióhoz prašek za peroralno suspenzijo
Diflucan 2 mg/ml oldatos infúzió 
Diflucan 2 mg/ml oldatos infúzió raztopina za infundiranje
Diflucan 10 mg/ml por belsőleges szuszpenzióhoz 
Diflucan 10 mg/ml por belsőleges szuszpenzióhoz prašek za peroralno suspenzijo
200 mg/100ml Solution for Infusion 
200 mg/100ml raztopina za infundiranje
Powder for Oral Suspension 
Fungustatin prašek za suspenzijo
Solution for Intravenous Infusion 
raztopina za infundiranje
Diflucan 50 mg/5 mlTrockensaft 
Diflucan 50 mg/5 mlTrockensaft prašek za peroralno suspenzijo
Diflucan 200 mg/5 mlTrockensaft 
Diflucan 200 mg/5 mlTrockensaft prašek za peroralno suspenzijo
In these two studies, patients were treated for four weeks. 
V teh dveh študijah so bolnike zdravili štiri tedne.
The additional study produced results that were consistent with those of the main studies. 
Rezultati dodatne študije so bili skladni z rezultati glavnih študij.
The European Commission granted a marketing authorisation valid throughout the European Union for Cayston on 21 September 2009. 
Evropska komisija je dovoljenje za promet z zdravilom Cayston, veljavno po vsej Evropski uniji, odobrila dne 21. septembra 2009.
EPAR summary for the public aztreonam 
Povzetek EPAR za javnost aztreonam
Other information about Cayston: 
Druge informacije o zdravilu Cayston:
The CHMP decided that Cayston's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Cayston večje od z njim povezanih tveganj, in priporočil, da se zanj odobri dovoljenje za promet.
This document is a summary of the European public assessment report (EPAR) for Cayston. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Cayston.
For more information about treatment with Cayston, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Cayston preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte s svojim zdravnikom ali farmacevtom.
Cayston is given three times a day for four weeks, with at least four hours between each dose. 
Zdravilo Cayston se daje štiri tedne trikrat na dan, med odmerki pa morajo preteči najmanj štiri ure.
The summary of the opinion of the Committee for Orphan Medicinal Products for Cayston can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation. 
Povzetek mnenja Odbora za zdravila sirote o zdravilu Cayston je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
What benefit has Cayston shown during the studies? 
Kakšne koristi je zdravilo Cayston izkazalo med študijami?
The main measure of effectiveness was based on improvements in patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second). 
Glavno merilo za učinkovitost je temeljilo na izboljšanju forsiranega ekspiracijskega volumna (FEV1 - največja prostornina zraka, ki ga lahko bolnik izdihne v eni sekundi).
In the second study, the main measure of effectiveness was how the patients rated their respiratory symptoms on a standard scale for cystic fibrosis. 
V drugi študiji je bilo glavno merilo učinkovitosti, kako so bolniki ocenili svoje dihalne simptome na standardni lestvici za cistično fibrozo.
A third main study involving 268 patients (including 59 children from six to 17 years of age) compared Cayston with another inhaled antibiotic (tobramycin nebuliser solution). 
Tretja glavna študija, ki je vključevala 268 bolnikov (vključno z 59 otroki, starimi od šest do 17 let), je primerjala zdravilo Cayston z drugim inhalacijskim antibiotikom (inhalacijska raztopino za nebulator s tobramicinom).
In patients with cystic fibrosis, P. aeruginosa infections usually start in the first 10 years of life and can cause long-term lung problems. 
Pri bolnikih s cistično fibrozo se okužbe z bakterijo P. aeruginosa običajno začnejo v prvih desetih letih življenja in lahko povzročajo dolgotrajne težave v pljučih.
This leads to problems with the digestion and absorption of food, resulting in poor growth, and long-term infection and inflammation of the lungs because of excess mucus not being cleared away. 
To povzroči težave s prebavo in absorpcijo hrane, kar privede do upočasnjene rasti, ter dolgotrajno okužbo in vnetje pljuč zaradi kopičenja čezmerne sluzi.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cayston. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Cayston, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Cayston must not be used in people who are hypersensitive (allergic) to aztreonam or any of the other ingredients. 
Zdravila Cayston ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) aztreonam ali katero koli drugo sestavino zdravila.
The full EPAR for Cayston can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Cayston je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Because the number of patients with bacterial lung infection in cystic fibrosis is low, the disease is considered ‘rare', and Cayston was designated an ‘orphan medicine' (a medicine used in rare diseases) on 21 June 2004. 
Ker je bolnikov s cistično fibrozo, ki imajo bakterijsko pljučno okužbo, malo, velja bolezen za redko, zato je bilo zdravilo Cayston 21. junija 2004 določeno kot „zdravilo sirota“ (zdravilo, ki se uporablja pri redkih boleznih).
In the first study, the main measure of effectiveness was how long it took before the patients needed other antibiotics by inhalation or injection into a vein. 
Glavno merilo učinkovitosti v prvi študiji je bil čas, preden je bolnik potreboval druge inhalacijske ali intravenozne antibiotike.
If the doctor thinks that further treatment cycles with Cayston are needed after the first course, a gap of four weeks is recommended after every four-week treatment cycle with Cayston. 
Če zdravnik meni, da so po prvem ciklu zdravljenja z zdravilom Cayston potrebni nadaljnji cikli zdravljenja, je priporočen štiritedenski premor po vsakem štiritedenskem ciklu z zdravilom Cayston.
It contains the active substance aztreonam. 
Vsebuje zdravilno učinkovino aztreonam.
For the full list of all side effects reported with Cayston, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov, o katerih so poročali pri uporabi zdravila Cayston, glejte navodilo za uporabo.
What is the risk associated with Cayston? 
Kakšna tveganja so povezana z zdravilom Cayston?
In the first study, the patients who received Cayston required other antibiotics after 92 days, compared with 71 days for the patients who received placebo. 
V eni študiji so bolniki, ki so prejemali zdravilo Cayston, druge antibiotike potrebovali po 92 dneh, bolniki, ki so prejemali placebo pa po 71 dneh.
The most common side effects with Cayston (seen in more than 1 patient in 10) are wheezing, cough, pharyngolaryngeal pain (pain in the throat and voice box), nasal congestion (blocked nose), dyspnoea (difficulty breathing) and fever. 
Najpogostejši neželeni učinki zdravila Cayston (opaženi pri več kot 1 bolniku od 10) so sopenje, kašelj, faringolaringalna bolečina (bolečina v grlu in govornem aparatu), zamašen nos in povišana telesna temperatura.
It looked at how well the lungs worked, the amount of P. aeruginosa bacteria in the patients' mucus and their respiratory symptoms. 
Proučevali so, kako dobro pljuča delujejo, količino bakterije P. aeruginosa v bolnikovi sluzi in dihalne simptome.
Cayston is to be used with a nebuliser (a special machine that changes the solution into an aerosol that the patient can breathe in). 
Zdravilo Cayston se mora uporabljati s pomočjo nebulatorja (posebne priprave, ki raztopino spremeni v aerosol, ki ga lahko bolnik vdihava).
Why has Cayston been approved? 
Zakaj je bilo zdravilo Cayston odobreno?
In the second study, respiratory symptoms improved in the patients who received Cayston, compared with the patients who received placebo. 
Druga študija je pokazala, da so se dihalni simptomi izboljšali pri bolnikih, ki so prejemali zdravilo Cayston, v primerjavi s tistimi, ki so prejemali placebo.
If the patient takes multiple inhaled treatments the bronchodilator should always be taken first, followed by a mucolytic (a medicine to make mucus thinner) and Cayston last. 
Če bolnik prejema več inhalacijskih oblik zdravljenja, je treba najprej vedno uporabiti bronhodilatator, čemur sledi mukolitik (zdravilo za redčenje sluzi) in nazadnje zdravilo Cayston.
Cayston was compared with placebo (a dummy treatment) in two main studies involving a total of 375 patients with cystic fibrosis who had long-term lung infection due to P.aeruginosa, most of whom were adults. 
Zdravilo Cayston so primerjali s placebom (zdravilom brez zdravilne učinkovine) v dveh glavnih študijah, v kateri je bilo skupaj vključeno 375 bolnikov s cistično fibrozo, ki so imeli dolgotrajno pljučno okužbo s P. aeruginosa in od katerih je bila večina odraslih.
The CHMP concluded that there was an unmet medical need for new antibiotics in patients with cystic fibrosis, since many of these patients have already developed resistance to other antibiotics by the time they reach adulthood, and because P. aeruginosa lung infections are a cause of severe health problems in patients with cystic fibrosis. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je ugotovil, da je obstajala potreba po novem antibiotiku za zdravljenje bolnikov s cistično fibrozo, saj številni bolniki do odrasle dobe že razvijejo odpornost na druge antibiotike, pljučne okužbe, ki jih povzroča bakterija P. aeruginosa, pa so vzrok za hude zdravstvene težave pri bolnikih s cistično fibrozo.
Cystic fibrosis is an inherited disease that affects the cells that secret mucus in the lungs and the cells that secret digestive juices from the glands in the gut and pancreas. 
Cistična fibroza je dedna bolezen, ki prizadene celice v pljučih, ki izločajo sluz, in celice, ki izločajo prebavne sokove iz žlez v črevesju ter trebušni slinavki.
In cystic fibrosis, the patient's lungs produce too much thick mucus, which allows bacteria to grow more easily. 
Pri cistični fibrozi v bolnikovih pljučih nastaja preveč goste sluzi, ki bakterijam omogoča lažjo rast.
The third study showed that Cayston compared favourably with the comparator antibiotic: after four weeks of treatment, the increase in FEV1 adjusted for age, height and sex was 8.35% with Cayston and 0.55% with the comparator; after three treatment cycles, the increase with Cayston was 2.05% compared with a decrease of 0.66% with the comparator. 
Tretja študija je pokazala, da je bilo zdravilo Cayston boljše kot primerjalni antibiotik: po štirih tednih zdravljenja je bilo povečanje FEV1, prilagojeno glede na starost, telesno višino in spol, 8,35 % pri zdravilu Cayston in 0,55 % pri primerjalnem zdravilu.
Cayston is used to suppress long-term lung infection caused by P. aeruginosa bacteria in adults and children aged six years or older with cystic fibrosis. 
Zdravilo Cayston se uporablja za zaviranje dolgotrajne pljučne okužbe, ki jo povzroči bakterija P. Aeruginosa pri odraslih bolnikih in otrocih (starih 6 let ali več) s cistično fibrozo.
An improvement in lung function was also seen in children aged six to 17 years, both after four weeks of treatment and after three treatment cycles. 
Izboljšanje pljučnega delovanja so po štirih tednih in treh ciklih zdravljenja opazili tudi pri otrocih, starih od šest do 17 let.
The active substance in Cayston, aztreonam, is an antibiotic that belongs to the group ‘beta-lactams'. 
Zdravilna učinkovina v zdravilu Cayston, aztreonam, je antibiotik, ki spada v skupino betalaktamov.